<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02137512</url>
  </required_header>
  <id_info>
    <org_study_id>Pilot 3 Outpatient CTR</org_study_id>
    <nct_id>NCT02137512</nct_id>
  </id_info>
  <brief_title>Pilot Study 3 of Outpatient Control-to-Range: Safety and Efficacy With Day-and-Night In-Home Use</brief_title>
  <acronym>CTR3</acronym>
  <official_title>Pilot Study 3 of Outpatient Control-to-Range: Safety and Efficacy With Day-and-Night In-Home Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jaeb Center for Health Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jaeb Center for Health Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if an automated insulin management system (&quot;study
      system&quot;) can safely be used at home to manage blood sugar. The study system includes (1) a
      CGM that measures glucose levels, (2) a computer program on a smartphone that determines how
      much insulin is needed and allows the study participant user to control the whole system, and
      (3) an insulin pump that delivers the insulin. The CGM will be from Dexcom. The pump will be
      from Roche. The CGM and pump are similar to the devices that are currently available for
      people to purchase and use. However, the smartphone device, the CGM sensor type used with it,
      and the overall study system can only be used for research at this time.

      The study will be completed by about 24 individuals at 6 centers in the United States and
      Europe. This study has several phases and will take about 11-14 weeks to complete depending
      on whether the study participant is a CGM user or not.

      At selected sites (based on subject eligibility and availability), approximately 10-20
      subjects who exhibit safe and competent use of the system at home will be given the option to
      continue home use of the system in Day-and-Night Closed-Loop mode for up to 5 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study phases are as follows:

        -  Screening visit to see if you are eligible for the study and to determine how long you
           will need to use the study CGM (visit 1)

        -  Up to 3 weeks using the study CGM (depends on your current CGM use), followed by an
           office visit (visit 2)

        -  2 weeks using the study insulin pump and study CGM together

        -  Full day visit in clinic or hotel for training using the system (visit 3)

        -  1 week using the system without automated insulin delivery or suspension

        -  2-day hotel or clinic visit for closed-loop training (visit 4),

        -  16-19 days using the system in the evening and overnight only followed by an office
           visit (visit 5)

        -  16-19 days using the system for the full 24 hours

        -  Final study clinic visit (visit 6)

        -  Option 5 month extension phase of day-and-night closed-loop home use
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time Spent &lt;70 mg/dL - Main Phase, Night Only</measure>
    <time_frame>2 weeks</time_frame>
    <description>Percentage of CGM Measured Glucose Values &lt;70 mg/dl during study Main Phase, night only (23:00 to 07:00)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time Spent &lt;70 mg/dL - Main Phase, Day and Night</measure>
    <time_frame>2 weeks</time_frame>
    <description>Percentage of CGM Measured Glucose Values &lt;70 mg/dl during study Main Phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Spent &lt;70 mg/dL - Main Phase, Day Only</measure>
    <time_frame>2 weeks</time_frame>
    <description>Percentage of CGM Measured Glucose Values &lt;70 mg/dl during study Main Phase, day only (07:00 - 23:00)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in Range 70-180 mg/dL - Main Phase, Day and Night</measure>
    <time_frame>2 weeks</time_frame>
    <description>Percentage of CGM Measured Glucose Values in range 70-180 mg/dl during study Main Phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in Range 70-180 mg/dL - Main Phase, Night Only</measure>
    <time_frame>2 weeks</time_frame>
    <description>Percentage of CGM Measured Glucose Values in range 70-180 mg/dl during study Main Phase, night only (23:00 - 07:00)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in Range 70-180 mg/dL - Main Phase, Day Only</measure>
    <time_frame>2 weeks</time_frame>
    <description>Percentage of CGM Measured Glucose Values in range 70-180 mg/dl during study Main Phase, day only (07:00 - 23:00)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Sensor Glucose - Main Phase, Day and Night</measure>
    <time_frame>2 weeks</time_frame>
    <description>Mean CGM sensor glucose during study Main Phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Sensor Glucose - Main Phase, Night Only</measure>
    <time_frame>2 weeks</time_frame>
    <description>Mean CGM sensor glucose during study Main Phase, night only (23:00 - 07:00)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Sensor Glucose - Main Phase, Day Only</measure>
    <time_frame>2 weeks</time_frame>
    <description>Mean CGM sensor glucose during study Main Phase, day only (07:00 - 23:00)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose Coefficient of Variation - Main Phase, Day and Night</measure>
    <time_frame>2 weeks</time_frame>
    <description>CGM Glucose Coefficient of Variation (CV) during study Main Phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose Coefficient of Variation - Main Phase, Night Only</measure>
    <time_frame>2 weeks</time_frame>
    <description>CGM Glucose Coefficient of Variation (CV) during study Main Phase, night only (23:00 - 07:00)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose Coefficient of Variation - Main Phase, Day Only</measure>
    <time_frame>2 weeks</time_frame>
    <description>CGM Glucose Coefficient of Variation (CV) during study Main Phase, day only (07:00 - 23:00)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose Standard Deviation - Main Phase, Day and Night</measure>
    <time_frame>2 weeks</time_frame>
    <description>CGM Glucose Standard Deviation (SD) during study Main Phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose Standard Deviation - Main Phase, Night Only</measure>
    <time_frame>2 weeks</time_frame>
    <description>CGM Glucose Standard Deviation (SD) during study Main Phase, night only (23:00 - 07:00)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose Standard Deviation - Main Phase, Day Only</measure>
    <time_frame>2 weeks</time_frame>
    <description>CGM Glucose Standard Deviation (SD) during study Main Phase, day only (07:00 - 23:00)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Spent &gt;180 mg/dL - Main Phase, Day and Night</measure>
    <time_frame>2 weeks</time_frame>
    <description>Percentage of CGM Measured Glucose Values &gt;180 mg/dl during study Main Phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Spent &gt;180 mg/dL - Main Phase, Night Only</measure>
    <time_frame>2 weeks</time_frame>
    <description>Percentage of CGM Measured Glucose Values &gt;180 mg/dl during study Main Phase, night only (23:00 to 07:00)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Spent &gt;180 mg/dL - Main Phase, Day Only</measure>
    <time_frame>2 weeks</time_frame>
    <description>Percentage of CGM Measured Glucose Values &gt;180 mg/dl during study Main Phase, day only (07:00 - 23:00)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Spent &lt;50 mg/dL - Main Phase, Day and Night</measure>
    <time_frame>2 weeks</time_frame>
    <description>Percentage of CGM Measured Glucose Values &lt;50 mg/dl during study Main Phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Spent &lt;50 mg/dL - Main Phase, Night Only</measure>
    <time_frame>2 weeks</time_frame>
    <description>Percentage of CGM Measured Glucose Values &lt;50 mg/dl during study Main Phase, night only (23:00 to 07:00)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Spent &lt;50 mg/dL - Main Phase, Day Only</measure>
    <time_frame>2 weeks</time_frame>
    <description>Percentage of CGM Measured Glucose Values &lt;50 mg/dl during study Main Phase, day only (07:00 - 23:00)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Spent &lt;60 mg/dL - Main Phase, Day and Night</measure>
    <time_frame>2 weeks</time_frame>
    <description>Percentage of CGM Measured Glucose Values &lt;60 mg/dl during study Main Phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Spent &lt;60 mg/dL - Main Phase, Night Only</measure>
    <time_frame>2 weeks</time_frame>
    <description>Percentage of CGM Measured Glucose Values &lt;60 mg/dl during study Main Phase, night only (23:00 - 07:00)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Spent &lt;60 mg/dL - Main Phase, Day Only</measure>
    <time_frame>2 weeks</time_frame>
    <description>Percentage of CGM Measured Glucose Values &lt;60 mg/dl during study Main Phase, day only (07:00 - 23:00)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LBGI - Main Phase, Day and Night</measure>
    <time_frame>2 weeks</time_frame>
    <description>Low Blood Glucose Index (LBGI) - Main Phase, Day and Night. The LGBI metric is used to quantify the risk of hypoglycemia. A higher LBGI implies more mild hypoglycemic events or less severe hypoglycemic events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LBGI - Main Phase, Night Only</measure>
    <time_frame>2 weeks</time_frame>
    <description>Low Blood Glucose Index (LBGI) - Main Phase, night only (23:00 - 07:00). The LGBI metric is used to quantify the risk of hypoglycemia. A higher LBGI implies more mild hypoglycemic events or less severe hypoglycemic events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LBGI - Main Phase, Day Only</measure>
    <time_frame>2 weeks</time_frame>
    <description>Low Blood Glucose Index (LBGI) - Main Phase, day only (07:00 - 23:00). The LGBI metric is used to quantify the risk of hypoglycemia. A higher LBGI implies more mild hypoglycemic events or less severe hypoglycemic events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AOC 70 mg/dL - Main Phase, Day and Night</measure>
    <time_frame>2 weeks</time_frame>
    <description>Area Over the Curve (AOC) 70 mg/dL - Main Phase, Day and Night. The hypoglycemia AOC is scaled to the number of CGM readings so the time factor cancels out. Technically, the units would be mg/dl, but this might seem unintuitive since it is incremental relative to a threshold. For example, a hypoglycemia AOC of 1 mg/dl can denote a glucose of 60 mg/dl for 10% of the time (10 mg/dl below threshold * 10% = 1 mg/dl) or 65 mg/dl for 20% of the time (5 mg/dl below threshold * 20% = 1 mg/dl). Note that it is based on relative (%) rather than absolute time so there is no time element in the resulting units.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AOC 70 mg/dL - Main Phase, Night Only</measure>
    <time_frame>2 weeks</time_frame>
    <description>Area Over the Curve (AOC) 70 mg/dL - Main Phase, night only (23:00 - 07:00). The hypoglycemia AOC is scaled to the number of CGM readings so the time factor cancels out. Technically, the units would be mg/dl, but this might seem unintuitive since it is incremental relative to a threshold. For example, a hypoglycemia AOC of 1 mg/dl can denote a glucose of 60 mg/dl for 10% of the time (10 mg/dl below threshold * 10% = 1 mg/dl) or 65 mg/dl for 20% of the time (5 mg/dl below threshold * 20% = 1 mg/dl). Note that it is based on relative (%) rather than absolute time so there is no time element in the resulting units.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AOC 70 mg/dL - Main Phase, Day Only</measure>
    <time_frame>2 weeks</time_frame>
    <description>Area Over the Curve (AOC) 70 mg/dL - Main Phase, day only (07:00 - 23:00). The hypoglycemia AOC is scaled to the number of CGM readings so the time factor cancels out. Technically, the units would be mg/dl, but this might seem unintuitive since it is incremental relative to a threshold. For example, a hypoglycemia AOC of 1 mg/dl can denote a glucose of 60 mg/dl for 10% of the time (10 mg/dl below threshold * 10% = 1 mg/dl) or 65 mg/dl for 20% of the time (5 mg/dl below threshold * 20% = 1 mg/dl). Note that it is based on relative (%) rather than absolute time so there is no time element in the resulting units.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBGI - Main Phase, Day and Night</measure>
    <time_frame>2 weeks</time_frame>
    <description>High Blood Glucose Index (HBGI) - Main Phase, Day and Night. The HBGI metric is used to quantify the risk of hyperglycemia. A higher HBGI implies more mild hyperglycemic events or less severe hyperglycemic events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBGI - Main Phase, Night Only</measure>
    <time_frame>2 weeks</time_frame>
    <description>High Blood Glucose Index (HBGI) - Main Phase, night only (23:00 - 07:00). The HBGI metric is used to quantify the risk of hyperglycemia. A higher HBGI implies more mild hyperglycemic events or less severe hyperglycemic events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBGI - Main Phase, Day Only</measure>
    <time_frame>2 weeks</time_frame>
    <description>High Blood Glucose Index (HBGI) - Main Phase, day only (07:00 - 23:00). The HBGI metric is used to quantify the risk of hyperglycemia. A higher HBGI implies more mild hyperglycemic events or less severe hyperglycemic events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADRR - Main Phase, Day and Night</measure>
    <time_frame>2 weeks</time_frame>
    <description>Average Daily Risk Range (ADRR) - Main Phase, Day and Night. ADRR is a metric that categorizes risk for hyper and hypoglycemic events. Low risk is scored 0-19, moderate risk is scored 20-40, and high risk is 40 and above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC 180 mg/dL - Main Phase, Day and Night</measure>
    <time_frame>2 weeks</time_frame>
    <description>Area Under the Curve (AUC) 180 mg/dL - Main Phase, Day and Night. The hyperglycemic AUC is scaled to the number of CGM readings so the time factor cancels out. Technically, the units would be mg/dl, but this might seem unintuitive since it is incremental relative to a threshold. For example, the hyperglycemic AUC is 28 (mg/dl)*days for Patient A and 56 (mg/dl)*days for Patient B when using 180 as the threshold. But this is artificial because Patient B wore the sensor twice as long. So we similarly scale it relative to the number of readings to reflect a mean rather than a sum. So we say hyperglycemic AUC = 4 mg/dl for both patients. Note that time disappears from the units in the scaled version. It represents the mean value of max(glucose-180, 0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC 180 mg/dL - Main Phase, Night Only</measure>
    <time_frame>2 weeks</time_frame>
    <description>Area Under the Curve (AUC) 180 mg/dL - Main Phase, night only (23:00 - 07:00). The hyperglycemic AUC is scaled to the number of CGM readings so the time factor cancels out. Technically, the units would be mg/dl, but this might seem unintuitive since it is incremental relative to a threshold. For example, the hyperglycemic AUC is 28 (mg/dl)*days for Patient A and 56 (mg/dl)*days for Patient B when using 180 as the threshold. But this is artificial because Patient B wore the sensor twice as long. So we similarly scale it relative to the number of readings to reflect a mean rather than a sum. So we say hyperglycemic AUC = 4 mg/dl for both patients. Note that time disappears from the units in the scaled version. It represents the mean value of max(glucose-180, 0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC 180 mg/dL - Main Phase, Day Only</measure>
    <time_frame>2 weeks</time_frame>
    <description>Area Under the Curve (AUC) 180 mg/dL - Main Phase, day only (07:00 - 23:00). The hyperglycemic AUC is scaled to the number of CGM readings so the time factor cancels out. Technically, the units would be mg/dl, but this might seem unintuitive since it is incremental relative to a threshold. For example, the hyperglycemic AUC is 28 (mg/dl)*days for Patient A and 56 (mg/dl)*days for Patient B when using 180 as the threshold. But this is artificial because Patient B wore the sensor twice as long. So we similarly scale it relative to the number of readings to reflect a mean rather than a sum. So we say hyperglycemic AUC = 4 mg/dl for both patients. Note that time disappears from the units in the scaled version. It represents the mean value of max(glucose-180, 0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Spent &gt;250 mg/dL - Main Phase, Day and Night</measure>
    <time_frame>2 weeks</time_frame>
    <description>Percentage of CGM Measured Glucose Values &gt;250 mg/dl during study Main Phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Spent &gt;250 mg/dL - Main Phase, Night Only</measure>
    <time_frame>2 weeks</time_frame>
    <description>Percentage of CGM Measured Glucose Values &gt;250 mg/dl during study Main Phase, night only (23:00 to 07:00)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Spent &gt;250 mg/dL - Main Phase, Day Only</measure>
    <time_frame>2 weeks</time_frame>
    <description>Percentage of CGM Measured Glucose Values &gt;250 mg/dl during study Main Phase, day only (07:00 - 23:00)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Spent &gt;300 mg/dL - Main Phase, Day and Night</measure>
    <time_frame>2 weeks</time_frame>
    <description>Percentage of CGM Measured Glucose Values &gt;300 mg/dl during study Main Phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Spent &gt;300 mg/dL - Main Phase, Night Only</measure>
    <time_frame>2 weeks</time_frame>
    <description>Percentage of CGM Measured Glucose Values &gt;300 mg/dl during study Main Phase, night only (23:00 to 07:00)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Spent &gt;300 mg/dL - Main Phase, Day Only</measure>
    <time_frame>2 weeks</time_frame>
    <description>Percentage of CGM Measured Glucose Values &gt;300 mg/dl during study Main Phase, day only (07:00 - 23:00)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mean Sensor Glucose - Extension Phase</measure>
    <time_frame>3 months</time_frame>
    <description>Mean CGM sensor glucose during Extension Phase</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in HbA1c - Extension Phase</measure>
    <time_frame>5 months</time_frame>
    <description>Comparison of HbA1c collected at baseline and at the end of the 5-month extension phase</description>
  </other_outcome>
  <other_outcome>
    <measure>Time Spent &lt;3.9 mmol/L (70 mg/dL) - Extension Phase</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage of CGM Measured Glucose Values &lt;3.9 mmol/L (70 mg/dL) during study Extension Phase</description>
  </other_outcome>
  <other_outcome>
    <measure>Time Spent &lt;3.3 mmol/L (60 mg/dL) - Extension Phase</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage of CGM Measured Glucose Values &lt;3.3 mmol/L (60 mg/dL) during study Extension Phase</description>
  </other_outcome>
  <other_outcome>
    <measure>Time Spent &lt;2.8 mmol/L (50 mg/dL) - Extension Phase</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage of CGM Measured Glucose Values &lt;2.8 mmol/L (50 mg/dL) during study Extension Phase</description>
  </other_outcome>
  <other_outcome>
    <measure>Time in Range 3.9-10.0 mmol/L (70-180 mg/dL) - Extension Phase</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage of CGM Measured Glucose Values in range 3.9-10.0 mmol/L (70-180 mg/dL)</description>
  </other_outcome>
  <other_outcome>
    <measure>Time Spent &gt;10.0 mmol/L (180 mg/dL) - Extension Phase</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage of CGM Measured Glucose Values &gt;10.0 mmol/L (180 mg/dL) during study Extension Phase</description>
  </other_outcome>
  <other_outcome>
    <measure>Time Spent &gt;13.9 mmol/L (250 mg/dL) - Extension Phase</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage of CGM Measured Glucose Values &gt;13.9 mmol/L (250 mg/dL) during study Extension Phase</description>
  </other_outcome>
  <other_outcome>
    <measure>Time Spent &gt;16.7 mmol/L (300 mg/dL) - Extension Phase</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage of CGM Measured Glucose Values &gt;16.7 mmol/L (300 mg/dL) during study Extension Phase</description>
  </other_outcome>
  <other_outcome>
    <measure>Episodes of Severe Hypoglycemia Events - Extension Phase</measure>
    <time_frame>5 months</time_frame>
    <description>Episodes of severe hypoglycemia events during the 5-month extension phase defined as an event requiring assistance of another person due to altered consciousness to actively administer carbohydrate, glucagon, or other resuscitative actions. This means that the subject was impaired cognitively to the point that he/she was unable to treat him or herself, was unable to verbalize his or her needs, was incoherent, disoriented, and/or combative, or experienced seizure or coma. These episodes may be associated with sufficient neuroglycopenia to induce seizure or coma. If plasma glucose measurements are not available during such an event, neurological recovery attributable to the restoration of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.</description>
  </other_outcome>
  <other_outcome>
    <measure>Episodes of Diabetic Ketoacidosis (DKA) Events - Extension Phase</measure>
    <time_frame>5 months</time_frame>
    <description>Episodes of DKA events that occurred during the 5-month extension phase</description>
  </other_outcome>
  <other_outcome>
    <measure>Reported Serious Adverse Events - Extension Phase</measure>
    <time_frame>5 months</time_frame>
    <description>Reported serious adverse events during the 5-month extension phase</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Closed-Loop Control System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of an investigational control-to-range automated insulin management (artificial pancreas) system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes in the home environment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sensor-Augmented Pump (SAP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Closed-Loop Control System</intervention_name>
    <description>This investigational device system included the following components:
DiAs - a smart-phone medical platform;
Dexcom G4 Platinum CGM system connected to DiAs via CGM receiver and USB-Bluetooth relay hardware;
Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth;
Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network
Modular Closed-Loop Control Algorithm Running on DiAs, which is of Control-to-Range (CTR) class</description>
    <arm_group_label>Closed-Loop Control System</arm_group_label>
    <other_name>Diabetes Assistant (DiAs)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sensor-Augmented Pump (SAP)</intervention_name>
    <description>This commercial device system included the following components:
Dexcom G4 Platinum CGM system;
Roche Accu-Chek insulin pump</description>
    <arm_group_label>Sensor-Augmented Pump (SAP)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least
             one year and using insulin for at least 1 year and an insulin pump for at least 6
             months.

          2. Age &gt;=18 to &lt;70 years.

          3. HbA1c &lt;10.0%; if HbA1c &lt;6.0% then total daily insulin must be &gt;=0.5 U/kg

          4. For females, not currently known to be pregnant. If female and sexually active, must
             agree to use a form of contraception to prevent pregnancy while a participant in the
             study. A negative urine pregnancy test will be required for all premenopausal women
             who are not surgically sterile. Subjects who become pregnant will be discontinued from
             the study.

          5. Demonstration of proper mental status and cognition for the study.

          6. Currently using insulin-to-carbohydrate ratio to calculate meal bolus sizes

          7. Hypoglycemia awareness as demonstrated by a Clarke Hypoglycemia Awareness score of 2
             or lower

          8. Access to internet and cell phone service at home, and a computer for downloading
             device data.

          9. Living with significant other or family member committed to participating in all
             training activities, knowledgeable at all times of the participant's location, and
             being present and available to provide assistance when system is being used at night.

         10. Commitment to maintaining uninterrupted availability via cell phone and avoiding any
             overnight travel for the duration of each two-week period using the closed-loop
             system.

         11. An understanding of and willingness to follow the protocol and sign the informed
             consent.

        Exclusion Criteria:

          1. Admission for diabetic ketoacidosis in the 12 months prior to enrollment.

          2. Severe hypoglycemia resulting in seizure or loss of consciousness in the 12 months
             prior to enrollment.

          3. History of a seizure disorder (except hypoglycemic seizure), unless written clearance
             is received from a neurologist.

          4. Coronary artery disease or heart failure, unless written clearance is received from a
             cardiologist.

          5. History of cardiac arrhythmia (except for benign premature atrial contractions and
             benign premature ventricular contractions which are permitted)

          6. Cystic fibrosis.

          7. A known medical condition that in the judgment of the investigator might interfere
             with the completion of the protocol such as the following examples:

               -  Inpatient psychiatric treatment in the past 6 months for either the subject or
                  the subject's primary care giver (i.e., parent or guardian)

               -  Presence of a known adrenal disorder

               -  Abnormal liver function test results (Transaminase &gt;2 times the upper limit of
                  normal); testing required for subjects taking medications known to affect liver
                  function or with diseases known to affect liver function

               -  Abnormal renal function test results (calculated GFR &lt;60); testing required for
                  subjects with diabetes duration of greater than 5 years post onset of puberty

               -  Active gastroparesis

               -  If on antihypertensive, thyroid, anti-depressant or lipid lowering medication,
                  lack of stability on the medication for the past 2 months prior to enrollment in
                  the study

               -  Uncontrolled thyroid disease (TSH undetectable or &gt;10); testing required within
                  three months prior to admission for subjects with a goiter, positive antibodies,
                  or who are on thyroid hormone replacement, and within one year otherwise

               -  Abuse of alcohol or recreational drugs

               -  Infectious process not anticipated to resolve prior to study procedures (e.g.
                  meningitis, pneumonia, osteomyelitis)

        7. A recent injury to body or limb, muscular disorder, use of any medication, any
        carcinogenic disease, or other significant medical disorder if that injury, medication or
        disease in the judgment of the investigator will affect the completion of the protocol 8.
        Current use of the following drugs and supplements:

          -  Acetaminophen

          -  Any medication being taken to lower blood glucose, such as Pramlintide, Metformin,
             GLP-1 Analogs such as Liraglutide, and nutraceuticals intended to lower blood glucose

          -  Beta blockers

          -  Oral or injectable glucocorticoids

          -  Any other medication that the investigator believes is a contraindication to the
             subject's participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roy Beck, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jaeb Center for Health Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Boris Kovatchev, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sansum Diabetes Research Institute</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montpellier University Hospital</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Center for Childhood Diabetes- Schneider Children's Medical Center</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49202</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Padova</name>
      <address>
        <city>Padova</city>
        <zip>93106</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/27208316</url>
    <description>Multinational Home Use of Closed-Loop Control Is Safe and Effective</description>
  </link>
  <results_reference>
    <citation>Anderson SM, Raghinaru D, Pinsker JE, Boscari F, Renard E, Buckingham BA, Nimri R, Doyle FJ 3rd, Brown SA, Keith-Hynes P, Breton MD, Chernavvsky D, Bevier WC, Bradley PK, Bruttomesso D, Del Favero S, Calore R, Cobelli C, Avogaro A, Farret A, Place J, Ly TT, Shanmugham S, Phillip M, Dassau E, Dasanayake IS, Kollman C, Lum JW, Beck RW, Kovatchev B; Control to Range Study Group. Multinational Home Use of Closed-Loop Control Is Safe and Effective. Diabetes Care. 2016 Jul;39(7):1143-50. doi: 10.2337/dc15-2468. Epub 2016 Apr 13.</citation>
    <PMID>27208316</PMID>
  </results_reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>May 12, 2014</study_first_submitted>
  <study_first_submitted_qc>May 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2014</study_first_posted>
  <results_first_submitted>April 27, 2016</results_first_submitted>
  <results_first_submitted_qc>August 26, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 19, 2016</results_first_posted>
  <last_update_submitted>October 26, 2018</last_update_submitted>
  <last_update_submitted_qc>October 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Artificial Pancreas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Closed-Loop Control System</title>
          <description>A control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes in the home environment.
Closed-Loop Control System: The devices that will be used in the Closed-Loop Control System include the following components:
DiAs – a smart-phone medical platform;
Dexcom Dexcom G4 Platinum connected to DiAs via CGM receiver and USB-Bluetooth relay hardware;
Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth;
Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network, and
Modular Closed-Loop Control Algorithm Running on DiAs, which is of Control-to-Range (CTR) class</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>2-Week Baseline Sensor-Augmented Pump</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>2-Week Overnight-Only Closed-Loop</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>2-Week 24/7 Closed-Loop</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>5-Month 24/7 Closed-Loop</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Closed-Loop Control System</title>
          <description>A control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes in the home environment.
Closed-Loop Control System: The devices that will be used in the Closed-Loop Control System include the following components:
DiAs – a smart-phone medical platform;
Dexcom Dexcom G4 Platinum connected to DiAs via CGM receiver and USB-Bluetooth relay hardware;
Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth;
Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network, and
Modular Closed-Loop Control Algorithm Running on DiAs, which is of Control-to-Range (CTR) class</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" lower_limit="18" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes duration</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19" lower_limit="13" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body-mass index (BMI)</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25" lower_limit="23" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1c (HbA1c)</title>
          <units>percent</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.3" lower_limit="7.1" upper_limit="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Daily total insulin dose</title>
          <units>U/kg/day</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.57" lower_limit="0.42" upper_limit="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Daily basal insulin</title>
          <units>U/kg/day</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.27" lower_limit="0.20" upper_limit="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time Spent &lt;70 mg/dL - Main Phase, Night Only</title>
        <description>Percentage of CGM Measured Glucose Values &lt;70 mg/dl during study Main Phase, night only (23:00 to 07:00)</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>Time Spent &lt;70 mg/dL - Main Phase, Night Only</title>
          <description>Percentage of CGM Measured Glucose Values &lt;70 mg/dl during study Main Phase, night only (23:00 to 07:00)</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>percentage of CGM values</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="1.1" upper_limit="6.3"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.2" upper_limit="1.6"/>
                    <measurement group_id="O3" value="0.4" lower_limit="0.2" upper_limit="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>No adjustments were made for multiple comparisons.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.31</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Spent &lt;70 mg/dL - Main Phase, Day and Night</title>
        <description>Percentage of CGM Measured Glucose Values &lt;70 mg/dl during study Main Phase</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>Time Spent &lt;70 mg/dL - Main Phase, Day and Night</title>
          <description>Percentage of CGM Measured Glucose Values &lt;70 mg/dl during study Main Phase</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>percentage of CGM values</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="2.0" upper_limit="7.8"/>
                    <measurement group_id="O2" value="2.6" lower_limit="1.6" upper_limit="3.6"/>
                    <measurement group_id="O3" value="1.7" lower_limit="1.1" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Spent &lt;70 mg/dL - Main Phase, Day Only</title>
        <description>Percentage of CGM Measured Glucose Values &lt;70 mg/dl during study Main Phase, day only (07:00 - 23:00)</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>Time Spent &lt;70 mg/dL - Main Phase, Day Only</title>
          <description>Percentage of CGM Measured Glucose Values &lt;70 mg/dl during study Main Phase, day only (07:00 - 23:00)</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>percentage of CGM values</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" lower_limit="2.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="3.2" lower_limit="2.1" upper_limit="4.6"/>
                    <measurement group_id="O3" value="2.3" lower_limit="1.3" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.10</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time in Range 70-180 mg/dL - Main Phase, Day and Night</title>
        <description>Percentage of CGM Measured Glucose Values in range 70-180 mg/dl during study Main Phase</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>Time in Range 70-180 mg/dL - Main Phase, Day and Night</title>
          <description>Percentage of CGM Measured Glucose Values in range 70-180 mg/dl during study Main Phase</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>percentage of CGM values</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="59" upper_limit="69"/>
                    <measurement group_id="O2" value="73" lower_limit="65" upper_limit="78"/>
                    <measurement group_id="O3" value="73" lower_limit="68" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.91</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time in Range 70-180 mg/dL - Main Phase, Night Only</title>
        <description>Percentage of CGM Measured Glucose Values in range 70-180 mg/dl during study Main Phase, night only (23:00 - 07:00)</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>Time in Range 70-180 mg/dL - Main Phase, Night Only</title>
          <description>Percentage of CGM Measured Glucose Values in range 70-180 mg/dl during study Main Phase, night only (23:00 - 07:00)</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>percentage of CGM values</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="53" upper_limit="73"/>
                    <measurement group_id="O2" value="75" lower_limit="69" upper_limit="80"/>
                    <measurement group_id="O3" value="72" lower_limit="65" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.20</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time in Range 70-180 mg/dL - Main Phase, Day Only</title>
        <description>Percentage of CGM Measured Glucose Values in range 70-180 mg/dl during study Main Phase, day only (07:00 - 23:00)</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>Time in Range 70-180 mg/dL - Main Phase, Day Only</title>
          <description>Percentage of CGM Measured Glucose Values in range 70-180 mg/dl during study Main Phase, day only (07:00 - 23:00)</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>percentage of CGM values</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="61" upper_limit="71"/>
                    <measurement group_id="O2" value="70" lower_limit="65" upper_limit="77"/>
                    <measurement group_id="O3" value="72" lower_limit="69" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.49</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Sensor Glucose - Main Phase, Day and Night</title>
        <description>Mean CGM sensor glucose during study Main Phase</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Sensor Glucose - Main Phase, Day and Night</title>
          <description>Mean CGM sensor glucose during study Main Phase</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157" spread="18"/>
                    <measurement group_id="O2" value="149" spread="12"/>
                    <measurement group_id="O3" value="153" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.009</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.14</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.06</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Sensor Glucose - Main Phase, Night Only</title>
        <description>Mean CGM sensor glucose during study Main Phase, night only (23:00 - 07:00)</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Sensor Glucose - Main Phase, Night Only</title>
          <description>Mean CGM sensor glucose during study Main Phase, night only (23:00 - 07:00)</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163" spread="23"/>
                    <measurement group_id="O2" value="150" spread="12"/>
                    <measurement group_id="O3" value="154" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.18</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Sensor Glucose - Main Phase, Day Only</title>
        <description>Mean CGM sensor glucose during study Main Phase, day only (07:00 - 23:00)</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Sensor Glucose - Main Phase, Day Only</title>
          <description>Mean CGM sensor glucose during study Main Phase, day only (07:00 - 23:00)</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154" spread="19"/>
                    <measurement group_id="O2" value="148" spread="15"/>
                    <measurement group_id="O3" value="152" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.07</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.54</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.07</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose Coefficient of Variation - Main Phase, Day and Night</title>
        <description>CGM Glucose Coefficient of Variation (CV) during study Main Phase</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Coefficient of Variation - Main Phase, Day and Night</title>
          <description>CGM Glucose Coefficient of Variation (CV) during study Main Phase</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>percentage</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38" lower_limit="34" upper_limit="41"/>
                    <measurement group_id="O2" value="35" lower_limit="33" upper_limit="37"/>
                    <measurement group_id="O3" value="34" lower_limit="31" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.02</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose Coefficient of Variation - Main Phase, Night Only</title>
        <description>CGM Glucose Coefficient of Variation (CV) during study Main Phase, night only (23:00 - 07:00)</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Coefficient of Variation - Main Phase, Night Only</title>
          <description>CGM Glucose Coefficient of Variation (CV) during study Main Phase, night only (23:00 - 07:00)</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>percentage</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="32" upper_limit="40"/>
                    <measurement group_id="O2" value="30" lower_limit="29" upper_limit="34"/>
                    <measurement group_id="O3" value="32" lower_limit="27" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.52</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose Coefficient of Variation - Main Phase, Day Only</title>
        <description>CGM Glucose Coefficient of Variation (CV) during study Main Phase, day only (07:00 - 23:00)</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Coefficient of Variation - Main Phase, Day Only</title>
          <description>CGM Glucose Coefficient of Variation (CV) during study Main Phase, day only (07:00 - 23:00)</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>percentage</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38" lower_limit="34" upper_limit="42"/>
                    <measurement group_id="O2" value="37" lower_limit="34" upper_limit="39"/>
                    <measurement group_id="O3" value="35" lower_limit="31" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.13</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose Standard Deviation - Main Phase, Day and Night</title>
        <description>CGM Glucose Standard Deviation (SD) during study Main Phase</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Standard Deviation - Main Phase, Day and Night</title>
          <description>CGM Glucose Standard Deviation (SD) during study Main Phase</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="53" upper_limit="69"/>
                    <measurement group_id="O2" value="52" lower_limit="48" upper_limit="58"/>
                    <measurement group_id="O3" value="51" lower_limit="47" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.41</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose Standard Deviation - Main Phase, Night Only</title>
        <description>CGM Glucose Standard Deviation (SD) during study Main Phase, night only (23:00 - 07:00)</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Standard Deviation - Main Phase, Night Only</title>
          <description>CGM Glucose Standard Deviation (SD) during study Main Phase, night only (23:00 - 07:00)</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="50" upper_limit="69"/>
                    <measurement group_id="O2" value="47" lower_limit="42" upper_limit="51"/>
                    <measurement group_id="O3" value="48" lower_limit="40" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.12</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose Standard Deviation - Main Phase, Day Only</title>
        <description>CGM Glucose Standard Deviation (SD) during study Main Phase, day only (07:00 - 23:00)</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Standard Deviation - Main Phase, Day Only</title>
          <description>CGM Glucose Standard Deviation (SD) during study Main Phase, day only (07:00 - 23:00)</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" lower_limit="53" upper_limit="65"/>
                    <measurement group_id="O2" value="55" lower_limit="49" upper_limit="60"/>
                    <measurement group_id="O3" value="53" lower_limit="47" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.02</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.06</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Spent &gt;180 mg/dL - Main Phase, Day and Night</title>
        <description>Percentage of CGM Measured Glucose Values &gt;180 mg/dl during study Main Phase</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>Time Spent &gt;180 mg/dL - Main Phase, Day and Night</title>
          <description>Percentage of CGM Measured Glucose Values &gt;180 mg/dl during study Main Phase</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>percentage of CGM values</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="25" upper_limit="36"/>
                    <measurement group_id="O2" value="24" lower_limit="20" upper_limit="31"/>
                    <measurement group_id="O3" value="25" lower_limit="22" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.26</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Spent &gt;180 mg/dL - Main Phase, Night Only</title>
        <description>Percentage of CGM Measured Glucose Values &gt;180 mg/dl during study Main Phase, night only (23:00 to 07:00)</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>Time Spent &gt;180 mg/dL - Main Phase, Night Only</title>
          <description>Percentage of CGM Measured Glucose Values &gt;180 mg/dl during study Main Phase, night only (23:00 to 07:00)</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>percentage of CGM values</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37" lower_limit="24" upper_limit="45"/>
                    <measurement group_id="O2" value="24" lower_limit="19" upper_limit="28"/>
                    <measurement group_id="O3" value="27" lower_limit="19" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.11</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Spent &gt;180 mg/dL - Main Phase, Day Only</title>
        <description>Percentage of CGM Measured Glucose Values &gt;180 mg/dl during study Main Phase, day only (07:00 - 23:00)</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>Time Spent &gt;180 mg/dL - Main Phase, Day Only</title>
          <description>Percentage of CGM Measured Glucose Values &gt;180 mg/dl during study Main Phase, day only (07:00 - 23:00)</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>percentage of CGM values</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" lower_limit="23" upper_limit="35"/>
                    <measurement group_id="O2" value="23" lower_limit="19" upper_limit="32"/>
                    <measurement group_id="O3" value="25" lower_limit="21" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.02</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.02</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.61</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Spent &lt;50 mg/dL - Main Phase, Day and Night</title>
        <description>Percentage of CGM Measured Glucose Values &lt;50 mg/dl during study Main Phase</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>Time Spent &lt;50 mg/dL - Main Phase, Day and Night</title>
          <description>Percentage of CGM Measured Glucose Values &lt;50 mg/dl during study Main Phase</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>percentage of CGM values</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.1" upper_limit="1.3"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0.1" upper_limit="0.5"/>
                    <measurement group_id="O3" value="0.2" lower_limit="0.0" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.29</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Spent &lt;50 mg/dL - Main Phase, Night Only</title>
        <description>Percentage of CGM Measured Glucose Values &lt;50 mg/dl during study Main Phase, night only (23:00 to 07:00)</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>Time Spent &lt;50 mg/dL - Main Phase, Night Only</title>
          <description>Percentage of CGM Measured Glucose Values &lt;50 mg/dl during study Main Phase, night only (23:00 to 07:00)</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>percentage of CGM values</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.0" upper_limit="1.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.99</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Spent &lt;50 mg/dL - Main Phase, Day Only</title>
        <description>Percentage of CGM Measured Glucose Values &lt;50 mg/dl during study Main Phase, day only (07:00 - 23:00)</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>Time Spent &lt;50 mg/dL - Main Phase, Day Only</title>
          <description>Percentage of CGM Measured Glucose Values &lt;50 mg/dl during study Main Phase, day only (07:00 - 23:00)</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>percentage of CGM values</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.1" upper_limit="1.2"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0.1" upper_limit="0.7"/>
                    <measurement group_id="O3" value="0.2" lower_limit="0.0" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.09</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Spent &lt;60 mg/dL - Main Phase, Day and Night</title>
        <description>Percentage of CGM Measured Glucose Values &lt;60 mg/dl during study Main Phase</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>Time Spent &lt;60 mg/dL - Main Phase, Day and Night</title>
          <description>Percentage of CGM Measured Glucose Values &lt;60 mg/dl during study Main Phase</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>percentage of CGM values</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="0.7" upper_limit="3.5"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.5" upper_limit="1.5"/>
                    <measurement group_id="O3" value="0.7" lower_limit="0.3" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Spent &lt;60 mg/dL - Main Phase, Night Only</title>
        <description>Percentage of CGM Measured Glucose Values &lt;60 mg/dl during study Main Phase, night only (23:00 - 07:00)</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>Time Spent &lt;60 mg/dL - Main Phase, Night Only</title>
          <description>Percentage of CGM Measured Glucose Values &lt;60 mg/dl during study Main Phase, night only (23:00 - 07:00)</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>percentage of CGM values</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.4" upper_limit="2.9"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0.0" upper_limit="0.6"/>
                    <measurement group_id="O3" value="0.1" lower_limit="0.0" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.26</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Spent &lt;60 mg/dL - Main Phase, Day Only</title>
        <description>Percentage of CGM Measured Glucose Values &lt;60 mg/dl during study Main Phase, day only (07:00 - 23:00)</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>Time Spent &lt;60 mg/dL - Main Phase, Day Only</title>
          <description>Percentage of CGM Measured Glucose Values &lt;60 mg/dl during study Main Phase, day only (07:00 - 23:00)</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>percentage of CGM values</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="0.8" upper_limit="3.5"/>
                    <measurement group_id="O2" value="1.4" lower_limit="0.7" upper_limit="1.9"/>
                    <measurement group_id="O3" value="0.7" lower_limit="0.4" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.04</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LBGI - Main Phase, Day and Night</title>
        <description>Low Blood Glucose Index (LBGI) - Main Phase, Day and Night. The LGBI metric is used to quantify the risk of hypoglycemia. A higher LBGI implies more mild hypoglycemic events or less severe hypoglycemic events.</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>LBGI - Main Phase, Day and Night</title>
          <description>Low Blood Glucose Index (LBGI) - Main Phase, Day and Night. The LGBI metric is used to quantify the risk of hypoglycemia. A higher LBGI implies more mild hypoglycemic events or less severe hypoglycemic events.</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>index scores</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.6" upper_limit="1.9"/>
                    <measurement group_id="O2" value="0.8" lower_limit="0.6" upper_limit="0.9"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.4" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LBGI - Main Phase, Night Only</title>
        <description>Low Blood Glucose Index (LBGI) - Main Phase, night only (23:00 - 07:00). The LGBI metric is used to quantify the risk of hypoglycemia. A higher LBGI implies more mild hypoglycemic events or less severe hypoglycemic events.</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>LBGI - Main Phase, Night Only</title>
          <description>Low Blood Glucose Index (LBGI) - Main Phase, night only (23:00 - 07:00). The LGBI metric is used to quantify the risk of hypoglycemia. A higher LBGI implies more mild hypoglycemic events or less severe hypoglycemic events.</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>index scores</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0.4" upper_limit="1.6"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.3" upper_limit="0.5"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.2" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.53</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LBGI - Main Phase, Day Only</title>
        <description>Low Blood Glucose Index (LBGI) - Main Phase, day only (07:00 - 23:00). The LGBI metric is used to quantify the risk of hypoglycemia. A higher LBGI implies more mild hypoglycemic events or less severe hypoglycemic events.</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>LBGI - Main Phase, Day Only</title>
          <description>Low Blood Glucose Index (LBGI) - Main Phase, day only (07:00 - 23:00). The LGBI metric is used to quantify the risk of hypoglycemia. A higher LBGI implies more mild hypoglycemic events or less severe hypoglycemic events.</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>index scores</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.8" upper_limit="1.7"/>
                    <measurement group_id="O2" value="0.9" lower_limit="0.7" upper_limit="1.2"/>
                    <measurement group_id="O3" value="0.7" lower_limit="0.4" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.05</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AOC 70 mg/dL - Main Phase, Day and Night</title>
        <description>Area Over the Curve (AOC) 70 mg/dL - Main Phase, Day and Night. The hypoglycemia AOC is scaled to the number of CGM readings so the time factor cancels out. Technically, the units would be mg/dl, but this might seem unintuitive since it is incremental relative to a threshold. For example, a hypoglycemia AOC of 1 mg/dl can denote a glucose of 60 mg/dl for 10% of the time (10 mg/dl below threshold * 10% = 1 mg/dl) or 65 mg/dl for 20% of the time (5 mg/dl below threshold * 20% = 1 mg/dl). Note that it is based on relative (%) rather than absolute time so there is no time element in the resulting units.</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>AOC 70 mg/dL - Main Phase, Day and Night</title>
          <description>Area Over the Curve (AOC) 70 mg/dL - Main Phase, Day and Night. The hypoglycemia AOC is scaled to the number of CGM readings so the time factor cancels out. Technically, the units would be mg/dl, but this might seem unintuitive since it is incremental relative to a threshold. For example, a hypoglycemia AOC of 1 mg/dl can denote a glucose of 60 mg/dl for 10% of the time (10 mg/dl below threshold * 10% = 1 mg/dl) or 65 mg/dl for 20% of the time (5 mg/dl below threshold * 20% = 1 mg/dl). Note that it is based on relative (%) rather than absolute time so there is no time element in the resulting units.</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.2" upper_limit="0.9"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.1" upper_limit="0.4"/>
                    <measurement group_id="O3" value="0.2" lower_limit="0.1" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AOC 70 mg/dL - Main Phase, Night Only</title>
        <description>Area Over the Curve (AOC) 70 mg/dL - Main Phase, night only (23:00 - 07:00). The hypoglycemia AOC is scaled to the number of CGM readings so the time factor cancels out. Technically, the units would be mg/dl, but this might seem unintuitive since it is incremental relative to a threshold. For example, a hypoglycemia AOC of 1 mg/dl can denote a glucose of 60 mg/dl for 10% of the time (10 mg/dl below threshold * 10% = 1 mg/dl) or 65 mg/dl for 20% of the time (5 mg/dl below threshold * 20% = 1 mg/dl). Note that it is based on relative (%) rather than absolute time so there is no time element in the resulting units.</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>AOC 70 mg/dL - Main Phase, Night Only</title>
          <description>Area Over the Curve (AOC) 70 mg/dL - Main Phase, night only (23:00 - 07:00). The hypoglycemia AOC is scaled to the number of CGM readings so the time factor cancels out. Technically, the units would be mg/dl, but this might seem unintuitive since it is incremental relative to a threshold. For example, a hypoglycemia AOC of 1 mg/dl can denote a glucose of 60 mg/dl for 10% of the time (10 mg/dl below threshold * 10% = 1 mg/dl) or 65 mg/dl for 20% of the time (5 mg/dl below threshold * 20% = 1 mg/dl). Note that it is based on relative (%) rather than absolute time so there is no time element in the resulting units.</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.1" upper_limit="0.6"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0.0" upper_limit="0.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.22</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AOC 70 mg/dL - Main Phase, Day Only</title>
        <description>Area Over the Curve (AOC) 70 mg/dL - Main Phase, day only (07:00 - 23:00). The hypoglycemia AOC is scaled to the number of CGM readings so the time factor cancels out. Technically, the units would be mg/dl, but this might seem unintuitive since it is incremental relative to a threshold. For example, a hypoglycemia AOC of 1 mg/dl can denote a glucose of 60 mg/dl for 10% of the time (10 mg/dl below threshold * 10% = 1 mg/dl) or 65 mg/dl for 20% of the time (5 mg/dl below threshold * 20% = 1 mg/dl). Note that it is based on relative (%) rather than absolute time so there is no time element in the resulting units.</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>AOC 70 mg/dL - Main Phase, Day Only</title>
          <description>Area Over the Curve (AOC) 70 mg/dL - Main Phase, day only (07:00 - 23:00). The hypoglycemia AOC is scaled to the number of CGM readings so the time factor cancels out. Technically, the units would be mg/dl, but this might seem unintuitive since it is incremental relative to a threshold. For example, a hypoglycemia AOC of 1 mg/dl can denote a glucose of 60 mg/dl for 10% of the time (10 mg/dl below threshold * 10% = 1 mg/dl) or 65 mg/dl for 20% of the time (5 mg/dl below threshold * 20% = 1 mg/dl). Note that it is based on relative (%) rather than absolute time so there is no time element in the resulting units.</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0.2" upper_limit="0.9"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.2" upper_limit="0.5"/>
                    <measurement group_id="O3" value="0.2" lower_limit="0.1" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HBGI - Main Phase, Day and Night</title>
        <description>High Blood Glucose Index (HBGI) - Main Phase, Day and Night. The HBGI metric is used to quantify the risk of hyperglycemia. A higher HBGI implies more mild hyperglycemic events or less severe hyperglycemic events.</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>HBGI - Main Phase, Day and Night</title>
          <description>High Blood Glucose Index (HBGI) - Main Phase, Day and Night. The HBGI metric is used to quantify the risk of hyperglycemia. A higher HBGI implies more mild hyperglycemic events or less severe hyperglycemic events.</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>index scores</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" lower_limit="5.9" upper_limit="7.8"/>
                    <measurement group_id="O2" value="5.0" lower_limit="4.3" upper_limit="6.2"/>
                    <measurement group_id="O3" value="5.5" lower_limit="4.6" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.26</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HBGI - Main Phase, Night Only</title>
        <description>High Blood Glucose Index (HBGI) - Main Phase, night only (23:00 - 07:00). The HBGI metric is used to quantify the risk of hyperglycemia. A higher HBGI implies more mild hyperglycemic events or less severe hyperglycemic events.</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>HBGI - Main Phase, Night Only</title>
          <description>High Blood Glucose Index (HBGI) - Main Phase, night only (23:00 - 07:00). The HBGI metric is used to quantify the risk of hyperglycemia. A higher HBGI implies more mild hyperglycemic events or less severe hyperglycemic events.</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>index scores</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="5.4" upper_limit="9.7"/>
                    <measurement group_id="O2" value="5.1" lower_limit="4.1" upper_limit="5.7"/>
                    <measurement group_id="O3" value="5.4" lower_limit="4.3" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.05</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HBGI - Main Phase, Day Only</title>
        <description>High Blood Glucose Index (HBGI) - Main Phase, day only (07:00 - 23:00). The HBGI metric is used to quantify the risk of hyperglycemia. A higher HBGI implies more mild hyperglycemic events or less severe hyperglycemic events.</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>HBGI - Main Phase, Day Only</title>
          <description>High Blood Glucose Index (HBGI) - Main Phase, day only (07:00 - 23:00). The HBGI metric is used to quantify the risk of hyperglycemia. A higher HBGI implies more mild hyperglycemic events or less severe hyperglycemic events.</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>index scores</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" lower_limit="5.2" upper_limit="8.0"/>
                    <measurement group_id="O2" value="5.1" lower_limit="4.4" upper_limit="7.1"/>
                    <measurement group_id="O3" value="5.5" lower_limit="4.7" upper_limit="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.02</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.52</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ADRR - Main Phase, Day and Night</title>
        <description>Average Daily Risk Range (ADRR) - Main Phase, Day and Night. ADRR is a metric that categorizes risk for hyper and hypoglycemic events. Low risk is scored 0-19, moderate risk is scored 20-40, and high risk is 40 and above.</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>ADRR - Main Phase, Day and Night</title>
          <description>Average Daily Risk Range (ADRR) - Main Phase, Day and Night. ADRR is a metric that categorizes risk for hyper and hypoglycemic events. Low risk is scored 0-19, moderate risk is scored 20-40, and high risk is 40 and above.</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>range scores</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="25" upper_limit="34"/>
                    <measurement group_id="O2" value="24" lower_limit="21" upper_limit="28"/>
                    <measurement group_id="O3" value="24" lower_limit="19" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.71</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC 180 mg/dL - Main Phase, Day and Night</title>
        <description>Area Under the Curve (AUC) 180 mg/dL - Main Phase, Day and Night. The hyperglycemic AUC is scaled to the number of CGM readings so the time factor cancels out. Technically, the units would be mg/dl, but this might seem unintuitive since it is incremental relative to a threshold. For example, the hyperglycemic AUC is 28 (mg/dl)*days for Patient A and 56 (mg/dl)*days for Patient B when using 180 as the threshold. But this is artificial because Patient B wore the sensor twice as long. So we similarly scale it relative to the number of readings to reflect a mean rather than a sum. So we say hyperglycemic AUC = 4 mg/dl for both patients. Note that time disappears from the units in the scaled version. It represents the mean value of max(glucose-180, 0).</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC 180 mg/dL - Main Phase, Day and Night</title>
          <description>Area Under the Curve (AUC) 180 mg/dL - Main Phase, Day and Night. The hyperglycemic AUC is scaled to the number of CGM readings so the time factor cancels out. Technically, the units would be mg/dl, but this might seem unintuitive since it is incremental relative to a threshold. For example, the hyperglycemic AUC is 28 (mg/dl)*days for Patient A and 56 (mg/dl)*days for Patient B when using 180 as the threshold. But this is artificial because Patient B wore the sensor twice as long. So we similarly scale it relative to the number of readings to reflect a mean rather than a sum. So we say hyperglycemic AUC = 4 mg/dl for both patients. Note that time disappears from the units in the scaled version. It represents the mean value of max(glucose-180, 0).</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="11.7" upper_limit="18.4"/>
                    <measurement group_id="O2" value="9.2" lower_limit="7.7" upper_limit="13.4"/>
                    <measurement group_id="O3" value="11.3" lower_limit="7.6" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.39</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC 180 mg/dL - Main Phase, Night Only</title>
        <description>Area Under the Curve (AUC) 180 mg/dL - Main Phase, night only (23:00 - 07:00). The hyperglycemic AUC is scaled to the number of CGM readings so the time factor cancels out. Technically, the units would be mg/dl, but this might seem unintuitive since it is incremental relative to a threshold. For example, the hyperglycemic AUC is 28 (mg/dl)*days for Patient A and 56 (mg/dl)*days for Patient B when using 180 as the threshold. But this is artificial because Patient B wore the sensor twice as long. So we similarly scale it relative to the number of readings to reflect a mean rather than a sum. So we say hyperglycemic AUC = 4 mg/dl for both patients. Note that time disappears from the units in the scaled version. It represents the mean value of max(glucose-180, 0).</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC 180 mg/dL - Main Phase, Night Only</title>
          <description>Area Under the Curve (AUC) 180 mg/dL - Main Phase, night only (23:00 - 07:00). The hyperglycemic AUC is scaled to the number of CGM readings so the time factor cancels out. Technically, the units would be mg/dl, but this might seem unintuitive since it is incremental relative to a threshold. For example, the hyperglycemic AUC is 28 (mg/dl)*days for Patient A and 56 (mg/dl)*days for Patient B when using 180 as the threshold. But this is artificial because Patient B wore the sensor twice as long. So we similarly scale it relative to the number of readings to reflect a mean rather than a sum. So we say hyperglycemic AUC = 4 mg/dl for both patients. Note that time disappears from the units in the scaled version. It represents the mean value of max(glucose-180, 0).</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7" lower_limit="7.9" upper_limit="26.4"/>
                    <measurement group_id="O2" value="8.4" lower_limit="5.7" upper_limit="11.0"/>
                    <measurement group_id="O3" value="9.1" lower_limit="6.4" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.06</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC 180 mg/dL - Main Phase, Day Only</title>
        <description>Area Under the Curve (AUC) 180 mg/dL - Main Phase, day only (07:00 - 23:00). The hyperglycemic AUC is scaled to the number of CGM readings so the time factor cancels out. Technically, the units would be mg/dl, but this might seem unintuitive since it is incremental relative to a threshold. For example, the hyperglycemic AUC is 28 (mg/dl)*days for Patient A and 56 (mg/dl)*days for Patient B when using 180 as the threshold. But this is artificial because Patient B wore the sensor twice as long. So we similarly scale it relative to the number of readings to reflect a mean rather than a sum. So we say hyperglycemic AUC = 4 mg/dl for both patients. Note that time disappears from the units in the scaled version. It represents the mean value of max(glucose-180, 0).</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC 180 mg/dL - Main Phase, Day Only</title>
          <description>Area Under the Curve (AUC) 180 mg/dL - Main Phase, day only (07:00 - 23:00). The hyperglycemic AUC is scaled to the number of CGM readings so the time factor cancels out. Technically, the units would be mg/dl, but this might seem unintuitive since it is incremental relative to a threshold. For example, the hyperglycemic AUC is 28 (mg/dl)*days for Patient A and 56 (mg/dl)*days for Patient B when using 180 as the threshold. But this is artificial because Patient B wore the sensor twice as long. So we similarly scale it relative to the number of readings to reflect a mean rather than a sum. So we say hyperglycemic AUC = 4 mg/dl for both patients. Note that time disappears from the units in the scaled version. It represents the mean value of max(glucose-180, 0).</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" lower_limit="9.6" upper_limit="17.9"/>
                    <measurement group_id="O2" value="10.0" lower_limit="7.7" upper_limit="15.3"/>
                    <measurement group_id="O3" value="9.8" lower_limit="7.5" upper_limit="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.02</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.86</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Spent &gt;250 mg/dL - Main Phase, Day and Night</title>
        <description>Percentage of CGM Measured Glucose Values &gt;250 mg/dl during study Main Phase</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>Time Spent &gt;250 mg/dL - Main Phase, Day and Night</title>
          <description>Percentage of CGM Measured Glucose Values &gt;250 mg/dl during study Main Phase</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>percentage of CGM values</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="4" upper_limit="11"/>
                    <measurement group_id="O2" value="4" lower_limit="3" upper_limit="7"/>
                    <measurement group_id="O3" value="5" lower_limit="3" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.74</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Spent &gt;250 mg/dL - Main Phase, Night Only</title>
        <description>Percentage of CGM Measured Glucose Values &gt;250 mg/dl during study Main Phase, night only (23:00 to 07:00)</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>Time Spent &gt;250 mg/dL - Main Phase, Night Only</title>
          <description>Percentage of CGM Measured Glucose Values &gt;250 mg/dl during study Main Phase, night only (23:00 to 07:00)</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>percentage of CGM values</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="3" upper_limit="14"/>
                    <measurement group_id="O2" value="3" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O3" value="4" lower_limit="2" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.09</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Spent &gt;250 mg/dL - Main Phase, Day Only</title>
        <description>Percentage of CGM Measured Glucose Values &gt;250 mg/dl during study Main Phase, day only (07:00 - 23:00)</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>Time Spent &gt;250 mg/dL - Main Phase, Day Only</title>
          <description>Percentage of CGM Measured Glucose Values &gt;250 mg/dl during study Main Phase, day only (07:00 - 23:00)</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>percentage of CGM values</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="3" upper_limit="10"/>
                    <measurement group_id="O2" value="5" lower_limit="3" upper_limit="6"/>
                    <measurement group_id="O3" value="5" lower_limit="3" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.07</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.68</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Spent &gt;300 mg/dL - Main Phase, Day and Night</title>
        <description>Percentage of CGM Measured Glucose Values &gt;300 mg/dl during study Main Phase</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>Time Spent &gt;300 mg/dL - Main Phase, Day and Night</title>
          <description>Percentage of CGM Measured Glucose Values &gt;300 mg/dl during study Main Phase</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>percentage of CGM values</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O3" value="1" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.62</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Spent &gt;300 mg/dL - Main Phase, Night Only</title>
        <description>Percentage of CGM Measured Glucose Values &gt;300 mg/dl during study Main Phase, night only (23:00 to 07:00)</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>Time Spent &gt;300 mg/dL - Main Phase, Night Only</title>
          <description>Percentage of CGM Measured Glucose Values &gt;300 mg/dl during study Main Phase, night only (23:00 to 07:00)</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>percentage of CGM values</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="6"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.23</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Spent &gt;300 mg/dL - Main Phase, Day Only</title>
        <description>Percentage of CGM Measured Glucose Values &gt;300 mg/dl during study Main Phase, day only (07:00 - 23:00)</description>
        <time_frame>2 weeks</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>2-Week Overnight-Only Closed-Loop</title>
            <description>Overnight-only home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
          <group group_id="O3">
            <title>2-Week 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 2-Week period</description>
          </group>
        </group_list>
        <measure>
          <title>Time Spent &gt;300 mg/dL - Main Phase, Day Only</title>
          <description>Percentage of CGM Measured Glucose Values &gt;300 mg/dl during study Main Phase, day only (07:00 - 23:00)</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>percentage of CGM values</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="2"/>
                    <measurement group_id="O3" value="1" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.67</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.09</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.22</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Sensor Glucose - Extension Phase</title>
        <description>Mean CGM sensor glucose during Extension Phase</description>
        <time_frame>3 months</time_frame>
        <population>One subject had missing CGM data at baseline and was not included in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>5-Month 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 5-Month period</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Sensor Glucose - Extension Phase</title>
          <description>Mean CGM sensor glucose during Extension Phase</description>
          <population>One subject had missing CGM data at baseline and was not included in this analysis</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="1.1"/>
                    <measurement group_id="O2" value="8.3" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.25</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in HbA1c - Extension Phase</title>
        <description>Comparison of HbA1c collected at baseline and at the end of the 5-month extension phase</description>
        <time_frame>5 months</time_frame>
        <population>One participant was excluded due to missing baseline CGM data</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>5-Month 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 5-Month period</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HbA1c - Extension Phase</title>
          <description>Comparison of HbA1c collected at baseline and at the end of the 5-month extension phase</description>
          <population>One participant was excluded due to missing baseline CGM data</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="0.6"/>
                    <measurement group_id="O2" value="7.0" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.23</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time Spent &lt;3.9 mmol/L (70 mg/dL) - Extension Phase</title>
        <description>Percentage of CGM Measured Glucose Values &lt;3.9 mmol/L (70 mg/dL) during study Extension Phase</description>
        <time_frame>3 months</time_frame>
        <population>One subject had missing CGM data at baseline and was not included in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>5-Month 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 5-Month period</description>
          </group>
        </group_list>
        <measure>
          <title>Time Spent &lt;3.9 mmol/L (70 mg/dL) - Extension Phase</title>
          <description>Percentage of CGM Measured Glucose Values &lt;3.9 mmol/L (70 mg/dL) during study Extension Phase</description>
          <population>One subject had missing CGM data at baseline and was not included in this analysis</population>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="2.9" upper_limit="7.5"/>
                    <measurement group_id="O2" value="1.3" lower_limit="0.6" upper_limit="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time Spent &lt;3.3 mmol/L (60 mg/dL) - Extension Phase</title>
        <description>Percentage of CGM Measured Glucose Values &lt;3.3 mmol/L (60 mg/dL) during study Extension Phase</description>
        <time_frame>3 months</time_frame>
        <population>One subject had missing CGM data at baseline and was not included in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>5-Month 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 5-Month period</description>
          </group>
        </group_list>
        <measure>
          <title>Time Spent &lt;3.3 mmol/L (60 mg/dL) - Extension Phase</title>
          <description>Percentage of CGM Measured Glucose Values &lt;3.3 mmol/L (60 mg/dL) during study Extension Phase</description>
          <population>One subject had missing CGM data at baseline and was not included in this analysis</population>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="1.5" upper_limit="3.4"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.2" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time Spent &lt;2.8 mmol/L (50 mg/dL) - Extension Phase</title>
        <description>Percentage of CGM Measured Glucose Values &lt;2.8 mmol/L (50 mg/dL) during study Extension Phase</description>
        <time_frame>3 months</time_frame>
        <population>One subject had missing CGM data at baseline and was not included in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>5-Month 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 5-Month period</description>
          </group>
        </group_list>
        <measure>
          <title>Time Spent &lt;2.8 mmol/L (50 mg/dL) - Extension Phase</title>
          <description>Percentage of CGM Measured Glucose Values &lt;2.8 mmol/L (50 mg/dL) during study Extension Phase</description>
          <population>One subject had missing CGM data at baseline and was not included in this analysis</population>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.8" upper_limit="1.3"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0.0" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time in Range 3.9-10.0 mmol/L (70-180 mg/dL) - Extension Phase</title>
        <description>Percentage of CGM Measured Glucose Values in range 3.9-10.0 mmol/L (70-180 mg/dL)</description>
        <time_frame>3 months</time_frame>
        <population>One subject had missing CGM data at baseline and was not included in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>5-Month 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 5-Month period</description>
          </group>
        </group_list>
        <measure>
          <title>Time in Range 3.9-10.0 mmol/L (70-180 mg/dL) - Extension Phase</title>
          <description>Percentage of CGM Measured Glucose Values in range 3.9-10.0 mmol/L (70-180 mg/dL)</description>
          <population>One subject had missing CGM data at baseline and was not included in this analysis</population>
          <units>percentage of CGM values in range</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66" lower_limit="59" upper_limit="69"/>
                    <measurement group_id="O2" value="77" lower_limit="73" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time Spent &gt;10.0 mmol/L (180 mg/dL) - Extension Phase</title>
        <description>Percentage of CGM Measured Glucose Values &gt;10.0 mmol/L (180 mg/dL) during study Extension Phase</description>
        <time_frame>3 months</time_frame>
        <population>One subject had missing CGM data at baseline and was not included in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>5-Month 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 5-Month period</description>
          </group>
        </group_list>
        <measure>
          <title>Time Spent &gt;10.0 mmol/L (180 mg/dL) - Extension Phase</title>
          <description>Percentage of CGM Measured Glucose Values &gt;10.0 mmol/L (180 mg/dL) during study Extension Phase</description>
          <population>One subject had missing CGM data at baseline and was not included in this analysis</population>
          <units>percentage of CGM values &gt;10.0 mmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" lower_limit="23" upper_limit="38"/>
                    <measurement group_id="O2" value="22" lower_limit="19" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.01</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time Spent &gt;13.9 mmol/L (250 mg/dL) - Extension Phase</title>
        <description>Percentage of CGM Measured Glucose Values &gt;13.9 mmol/L (250 mg/dL) during study Extension Phase</description>
        <time_frame>3 months</time_frame>
        <population>One subject had missing CGM data at baseline and was not included in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>5-Month 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 5-Month period</description>
          </group>
        </group_list>
        <measure>
          <title>Time Spent &gt;13.9 mmol/L (250 mg/dL) - Extension Phase</title>
          <description>Percentage of CGM Measured Glucose Values &gt;13.9 mmol/L (250 mg/dL) during study Extension Phase</description>
          <population>One subject had missing CGM data at baseline and was not included in this analysis</population>
          <units>percentage of CGM values in range</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="3" upper_limit="11"/>
                    <measurement group_id="O2" value="3" lower_limit="2" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time Spent &gt;16.7 mmol/L (300 mg/dL) - Extension Phase</title>
        <description>Percentage of CGM Measured Glucose Values &gt;16.7 mmol/L (300 mg/dL) during study Extension Phase</description>
        <time_frame>3 months</time_frame>
        <population>One subject had missing CGM data at baseline and was not included in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>2-Week Baseline Sensor-Augmented Pump</title>
            <description>Home use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump for a 2-Week period</description>
          </group>
          <group group_id="O2">
            <title>5-Month 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 5-Month period</description>
          </group>
        </group_list>
        <measure>
          <title>Time Spent &gt;16.7 mmol/L (300 mg/dL) - Extension Phase</title>
          <description>Percentage of CGM Measured Glucose Values &gt;16.7 mmol/L (300 mg/dL) during study Extension Phase</description>
          <population>One subject had missing CGM data at baseline and was not included in this analysis</population>
          <units>percentage of CGM values in range</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.14</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Episodes of Severe Hypoglycemia Events - Extension Phase</title>
        <description>Episodes of severe hypoglycemia events during the 5-month extension phase defined as an event requiring assistance of another person due to altered consciousness to actively administer carbohydrate, glucagon, or other resuscitative actions. This means that the subject was impaired cognitively to the point that he/she was unable to treat him or herself, was unable to verbalize his or her needs, was incoherent, disoriented, and/or combative, or experienced seizure or coma. These episodes may be associated with sufficient neuroglycopenia to induce seizure or coma. If plasma glucose measurements are not available during such an event, neurological recovery attributable to the restoration of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.</description>
        <time_frame>5 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>5-Month 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 5-Month period</description>
          </group>
        </group_list>
        <measure>
          <title>Episodes of Severe Hypoglycemia Events - Extension Phase</title>
          <description>Episodes of severe hypoglycemia events during the 5-month extension phase defined as an event requiring assistance of another person due to altered consciousness to actively administer carbohydrate, glucagon, or other resuscitative actions. This means that the subject was impaired cognitively to the point that he/she was unable to treat him or herself, was unable to verbalize his or her needs, was incoherent, disoriented, and/or combative, or experienced seizure or coma. These episodes may be associated with sufficient neuroglycopenia to induce seizure or coma. If plasma glucose measurements are not available during such an event, neurological recovery attributable to the restoration of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Episodes of Diabetic Ketoacidosis (DKA) Events - Extension Phase</title>
        <description>Episodes of DKA events that occurred during the 5-month extension phase</description>
        <time_frame>5 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>5-Month 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 5-Month period</description>
          </group>
        </group_list>
        <measure>
          <title>Episodes of Diabetic Ketoacidosis (DKA) Events - Extension Phase</title>
          <description>Episodes of DKA events that occurred during the 5-month extension phase</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Reported Serious Adverse Events - Extension Phase</title>
        <description>Reported serious adverse events during the 5-month extension phase</description>
        <time_frame>5 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>5-Month 24/7 Closed-Loop</title>
            <description>24/7 (night and day) home use of a control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes for a 5-Month period</description>
          </group>
        </group_list>
        <measure>
          <title>Reported Serious Adverse Events - Extension Phase</title>
          <description>Reported serious adverse events during the 5-month extension phase</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12-weeks during the main portion of the study and 5 months in the optional extension phase of the study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Closed-Loop Control System</title>
          <description>A control-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes in the home environment.
Closed-Loop Control System: The devices that will be used in the Closed-Loop Control System include the following components:
DiAs – a smart-phone medical platform;
Dexcom Dexcom G4 Platinum connected to DiAs via CGM receiver and USB-Bluetooth relay hardware;
Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth;
Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network, and
Modular Closed-Loop Control Algorithm Running on DiAs, which is of Control-to-Range (CTR) class</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Ketosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Was assessed by site principal investigator and study medical monitor as unrelated to study device and/or procedure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cold</sub_title>
                <description>Was assessed by site principal investigator and study medical monitor as unrelated to study device and/or procedure.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tooth Infection</sub_title>
                <description>Was assessed by site principal investigator and study medical monitor as unrelated to study device and/or procedure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Skin injury</sub_title>
                <description>Was assessed by site principal investigator and study medical monitor as unrelated to study device and/or procedure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Shoulder Pain</sub_title>
                <description>Was assessed by site principal investigator and study medical monitor as unrelated to study device and/or procedure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>Was assessed by site principal investigator and study medical monitor as unrelated to study device and/or procedure.</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometriosis</sub_title>
                <description>Was assessed by site principal investigator and study medical monitor as unrelated to study device and/or procedure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus Infection</sub_title>
                <description>Was assessed by site principal investigator and study medical monitor as unrelated to study device and/or procedure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <description>Was assessed by site principal investigator and study medical monitor as unrelated to study device and/or procedure.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <description>Was assessed by site principal investigator and study medical monitor as unrelated to study device and/or procedure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Was assessed by site principal investigator and study medical monitor as unrelated to study device and/or procedure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John Lum, Artificial Pancreas Project Director</name_or_title>
      <organization>Jaeb Center for Health Research</organization>
      <phone>8139758690</phone>
      <email>jlum@jaeb.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

